Advance in herpes simplex viruses for cancer therapy

Science China Life Sciences

Volumn 56, Issue 4, 2013, Pages 298-305

  Liu, ShangLong ^a   Dai, MeiHua ^a   You, Lei ^a   Zhao, YuPei ^a  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

Author keywords

cancer; gene therapy; herpesvirus; oncolytic viruses; virotherapy

Indexed keywords

EID: 84876108347     PISSN: 16747305     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11427-013-4466-4     Document Type: Review

References (77)

1. Parkin D M, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin, 2005, 55: 74-108.
2. Wong H H, Lemoine N R. Biological approaches to therapy of pancreatic cancer. Pancreatology, 2008, 8: 431-461.
3. Thorne S H. Immunotherapeutic potential of oncolytic vaccinia virus. Immunol Res, 2011, 50: 286-293.
4. Cross D, Burmester J K. Gene therapy for cancer treatment: past, present and future. Clin Med Res, 2006, 4: 218-227.
5. Dai M H, Zamarin D, Gao S P, et al. Synergistic action of oncolytic herpes simplex virus and radiotherapy in pancreatic cancer cell lines. Br J Surg, 2010, 97: 1385-1394.
6. Eisenberg D P, Adusumilli P S, Hendershott K J, et al. 5-fluorouracil and gemcitabine potentiate the efficacy of oncolytic herpes viral gene therapy in the treatment of pancreatic cancer. J Gastrointest Surg, 2005, 9: 1068-1077.
7. Hartkopf A D, Fehm T, Wallwiener D, et al. Oncolytic virotherapy of gynecologic malignancies. Gynecol Oncol, 2011, 120: 302-310.
8. Dingwell K S, Johnson D C. The herpes simplex virus gE-gI complex facilitatescell-to-cell spread and binds to components of cell junctions. J Virol, 1998, 72: 8933-8942.
9. De Clercq E. Antiviral drugs in current clinical use. J Clin Virol, 2004, 30: 115-133.
10. Todo T. "Armed" oncolytic herpes simplex viruses for brain tumor therapy. Cell Adh Migr, 2008, 2: 208-213.
11. McGeoch D J, Dalrymple M A, Davison A J, et al. The complete DNA sequence of the long unique region in the genome of herpes simplex virus type 1. J Gen Virol, 1988, 69: 1531-1574.
12. Eager R M, Nemunaitis J. Clinical development directions in oncolytic viral therapy. Cancer Gene Ther, 2011, 18: 305-317.
13. Chou J, Kern E R, Whitley R J, et al. Mapping of herpes simplex virus-1 neurovirulence to gamma 134. 5, a gene nonessential for growth in culture. Science, 1990, 250: 1262-1266.
14. Walker J D, Sehgal I, Kousoulas K G. Oncolytic herpes simplex virus 1 encoding 15-prostaglandin dehydrogenase mitigates immune suppression and reduces ectopic primary and metastatic breast cancer in mice. J Virol, 2011, 85: 7363-7371.
15. Haseley A, Alvarez-Breckenridge C, Chaudhury A R, et al. Advances in oncolytic virus therapy for glioma. Recent Pat CNS Drug Discov, 2009, 4: 1-13.
16. Conrady C D, Drevets D A, Carr D J. Herpes simplex type I (HSV-1) infection of the nervous system: is an immune response a good thing? J Neuroimmunol, 2010, 220: 1-9.
17. Kanai R, Wakimoto H, Cheema T, et al. Oncolytic herpes simplex virus vectors and chemotherapy: are combinatorial strategies more effective for cancer? Future Oncol, 2010, 6: 619-634.
18. Fong Y, Kim T, Bhargava A, et al. A herpes oncolytic virus can be delivered via the vasculature to produce biologic changes in human colorectal cancer. Mol Ther, 2009, 17: 389-394.
19. Martuza R L, Malick A, Markert J M, et al. Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science, 1991, 252: 854-856.
20. Markert J M, Coen D M, Malick A, et al. Expanded spectrum of viral therapy in the treatment of nervous system tumors. J Neurosurg, 1992, 77: 590-594.
21. Markert J M, Malick A, Coen D M, et al. Reduction and elimination of encephalitis in an experimental glioma therapy model with attenuated herpes simplex mutants that retain susceptibility to acyclovir. Neurosurgery, 1993, 32: 597-603.
22. Shirota T, Kasuya H, Kodera Y, et al. Oncolytic herpes virus induces effective anti-cancer immunity against murine colon cancer. Hepatogastroenterology, 2011, 58: 1482-1489.
23. Watanabe I, Kasuya H, Nomura N, et al. Effects of tumor selective replication-competent herpes viruses in combination with gemcitabine on pancreatic cancer. Cancer Chemother Pharmacol, 2008, 61: 875-882.
24. Kanzaki A, Kasuya H, Yamamura K, et al. Antitumor efficacy of oncolytic herpes simplex virus adsorbed onto antigen-specific lymphocytes. Cancer Gene Ther, 2012, 19: 292-298.
25. Samoto K, Ehtesham M, Perng G C, et al. A herpes simplex virus type 1 mutant with gamma 34. 5 and LAT deletions effectively oncolyses human U87 glioblastomas in nude mice. Neurosurgery, 2002, 50: 599-605.
26. Samoto K, Perng G C, Ehtesham M, et al. A herpes simplex virus type 1 mutant deleted for gamma34. 5 and LAT kills glioma cells in vitro and is inhibited for in vivo reactivation. Cancer Gene Ther, 2001, 8: 269-277.
27. Kroeger K M, Muhammad A K, Baker G J, et al. Gene therapy and virotherapy: novel therapeutic approaches for brain tumors. Discov Med, 2010, 10: 293-304.
28. Wang J N, Hu P, Zeng M S, et al. Anti-tumor effect of oncolytic herpes simplex virus G47delta on human nasopharyngeal carcinoma. Chin J Cancer, 2011, 30: 831-841.
29. Passer B J, Wu C L, Wu S, et al. Analysis of genetically engineered oncolytic herpes simplex viruses in human prostate cancer organotypic cultures. Gene Ther, 2009, 16: 1477-1482.
30. Fukuhara H, Martuza R L, Rabkin S D, et al. Oncolytic herpes simplex virus vector g47delta in combination with androgen ablation for the treatment of human prostate adenocarcinoma. Clin Cancer Res, 2005, 11: 7886-7890.
31. Kelly K J, Wong J, Fong Y. Herpes simplex virus NV1020 as a novel and promising therapy for hepatic malignancy. Expert Opin Investig Drugs, 2008, 17: 1105-1113.
32. McAuliffe P F, Jarnagin W R, Johnson P, et al. Effective treatment of pancreatic tumors with two multimutated herpes simplex oncolytic viruses. J Gastrointest Surg, 2000, 4: 580-588.
33. Gutermann A, Mayer E, von Dehn-Rothfelser K, et al. Efficacy of oncolytic herpesvirus NV1020 can be enhanced by combination with chemotherapeutics in colon carcinoma cells. Hum Gene Ther, 2006, 17: 1241-1253.
34. Cozzi P J, Malhotra S, McAuliffe P, et al. Intravesical oncolytic viral therapy using attenuated, replication-competent herpes simplex viruses G207 and Nv1020 is effective in the treatment of bladder cancer in an orthotopic syngeneic model. FASEB J, 2001, 15: 1306-1308.
35. Ebright M I, Zager J S, Malhotra S, et al. Replication-competent herpes virus NV1020 as direct treatment of pleural cancer in a rat model. J Thorac Cardiovasc Surg, 2002, 124: 123-129.
36. Kemeny N, Brown K, Covey A, et al. Phase I, open-label, dose-escalating study of a genetically engineered herpes simplex virus, NV1020, in subjects with metastatic colorectal carcinoma to the liver. Hum Gene Ther, 2006, 17: 1214-1224.
37. Geevarghese S K, Geller D A, de Haan H A, et al. Phase I/II study of oncolytic herpes simplex virus NV1020 in patients with extensively pretreated refractory colorectal cancer metastatic to the liver. Hum Gene Ther, 2010, 21: 1119-1128.
38. Fujiwara S, Nawa A, Luo C, et al. Carrier cell-based delivery of replication-competent HSV-1 mutants enhances antitumor effect for ovarian cancer. Cancer Gene Ther, 2011, 18: 77-86.
39. Watanabe D, Goshima F, Mori I, et al. Oncolytic virotherapy for malignant melanoma with herpes simplex virus type 1 mutant HF10. J Dermatol Sci, 2008, 50: 185-196.
40. Kimata H, Imai T, Kikumori T, et al. Pilot study of oncolytic viral therapy using mutant herpes simplex virus (HF10) against recurrent metastatic breast cancer. Ann Surg Oncol, 2006, 13: 1078-1084.
41. Nakao A, Kasuya H, Sahin T T, et al. A phase I dose-escalation clinical trial of intraoperative direct intratumoral injection of HF10 oncolytic virus in non-resectable patients with advanced pancreatic cancer. Cancer Gene Ther, 2011, 18: 167-175.
42. Sahin T T, Kasuya H, Nomura N, et al. Impact of novel oncolytic virus HF10 on cellular components of the tumor microenvironment in patients with recurrent breast cancer. Cancer Gene Ther, 2012, 19: 229-237.
43. Rampling R, Cruickshank G, Papanastassiou V, et al. Toxicity evaluation of replication-competent herpes simplex virus (ICP 34. 5 null mutant 1716) in patients with recurrent malignant glioma. Gene Ther, 2000, 7: 859-866.
44. Mace A T, Ganly I, Soutar D S, et al. Potential for efficacy of the oncolytic herpes simplex virus 1716 in patients with oral squamous cell carcinoma. Head & Neck, 2008, 30: 1045-1051.
45. Papanastassiou V, Rampling R, Fraser M, et al. The potential for efficacy of the modified (ICP 34. 5(-)) herpes simplex virus HSV1716 following intratumoural injection into human malignant glioma: a proof of principle study. Gene Ther, 2002, 9: 398-406.
46. Harrow S, Papanastassiou V, Harland J, et al. HSV1716 injection into the brain adjacent to tumour following surgical resection of high-grade glioma: safety data and long-term survival. Gene Ther, 2004, 11: 1648-1658.
47. Hu J C, Coffin R S, Davis C J, et al. A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor. Clin Cancer Res, 2006, 12: 6737-6747.
48. Kaufman H L, Kim D W, DeRaffele G, et al. Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma. Ann Surg Oncol, 2010, 17: 718-730.
49. Kaufman H L, Bines S D. OPTIM trial: a Phase III trial of an oncolytic herpes virus encoding GM-CSF for unresectable stage III or IV melanoma. Future Oncol, 2010, 6: 941-949.
50. OPTiM OncoVEXGM-CSF Phase III Trial in Melanoma. www. oncovexgmcsf. com.
51. Fu X, Tao L, Cai R, et al. A mutant type 2 herpes simplex virus deleted for the protein kinase domain of the ICP10 gene is a potent oncolytic virus. Mol Ther, 2006, 13: 882-890.
52. Fu X, Nakamori M, Tao L, et al. Antitumor effects of two newly constructed oncolytic herpes simplex viruses against renal cell carcinoma. Int J Oncol, 2007, 30: 1561-1567.
53. Fu X, Tao L, Zhang X. An oncolytic virus derived from type 2 herpes simplex virus has potent therapeutic effect against metastatic ovarian cancer. Cancer Gene Ther, 2007, 14: 480-487.
54. Fu X, Tao L, Li M, et al. Effective treatment of pancreatic cancer xenografts with a conditionally replicating virus derived from type 2 herpes simplex virus. Clin Cancer Res, 2006, 12: 3152-3157.
55. Li H, Dutuor A, Fu X, et al. Induction of strong antitumor immunity by an HSV-2-based oncolytic virus in a murine mammary tumor model. J Gene Med, 2007, 9: 161-169.
56. Li H, Zeng Z, Fu X, et al. Coadministration of a herpes simplex virus-2 based oncolytic virus and cyclophosphamide produces a synergistic antitumor effect and enhances tumor-specific immune responses. Cancer Res, 2007, 67: 7850-7855.
57. Post D E, Fulci G, Chiocca E A, et al. Replicative oncolytic herpes simplex viruses in combination cancer therapies. Curr Gene Ther, 2004, 4: 41-51.
58. Blank S V, Rubin S C, Coukos G, et al. Replication-selective herpes simplex virus type 1 mutant therapy of cervical cancer is enhanced by low-dose radiation. Hum Gene Ther, 2002, 13: 627-639.
59. Passer B J, Castelo-Branco P, Buhrman J S, et al. Oncolytic herpes simplex virus vectors and taxanes synergize to promote killing of prostate cancer cells. Cancer Gene Ther, 2009, 16: 551-560.
60. Advani S J, Mezhir J J, Roizman B, et al. ReVOLT: radiation-enhanced viral oncolytic therapy. Int J Radiat Oncol Biol Phys, 2006, 66: 637-646.
61. Ottolino-Perry K, Diallo J S, Lichty B D, et al. Intelligent design: combination therapy with oncolytic viruses. Mol Ther, 2010, 18: 251-263.
62. Kim S H, Wong R J, Kooby D A, et al. Combination of mutated herpes simplex virus type 1 (G207 virus) with radiation for the treatment of squamous cell carcinoma of the head and neck. Eur J Cancer, 2005, 41: 313-322.
63. Jarnagin W R, Zager J S, Hezel M, et al. Treatment of cholangio-carcinoma with oncolytic herpes simplex virus combined with external beam radiation therapy. Cancer Gene Ther, 2006, 13: 326-334.
64. Adusumilli P S, Stiles B M, Chan M K, et al. Radiation therapy potentiates effective oncolytic viral therapy in the treatment of lung cancer. Ann Thorac Surg, 2005, 80: 409-417.
65. Stanziale S F, Petrowsky H, Joe J K, et al. Ionizing radiation potentiates the antitumor efficacy of oncolytic herpes simplex virus G207 by upregulating ribonucleotide reductase. Surgery, 2002, 132: 353-359.
66. Petrowsky H, Roberts G, Kooby D A, et al. Functional interaction between fluorodeoxyuridine-induced cellular alterations and replication of a ribonucleotide reductase-negative herpes simplex virus. J Virol, 2001, 75: 7050-7108.
67. Hu J C, Hallden G, Shorrock C, et al. Combination of a second generation genetically modified herpes simplex virus 1 (HSV1) with paclitaxel in the treatment of breast cancer in vitro. In: ASCO Annual Meeting Proceedings, 2004. 22: 723.
68. Ottolino-Perry K, Diallo J S, Lichty B D, et al. Intelligent design: combination therapy with oncolytic viruses. Mol Ther, 2010, 18: 251-263.
69. Wong H H, Lemoine N R, Wang Y. Oncolytic viruses for cancer therapy: overcoming the obstacles. Viruses, 2010, 2: 78-106.
70. Shah A C, Benos D, Gillespie G Y, et al. Oncolytic viruses: clinical applications as vectors for the treatment of malignant gliomas. J Neurooncol, 2003, 65: 203-226.
71. Wong R J, Chan M K, Yu Z, et al. Angiogenesis inhibition by an oncolytic herpes virus expressing interleukin 12. Clin Cancer Res, 2004, 10: 4509-4516.
72. Derubertis B G, Stiles B M, Bhargava A, et al. Cytokine-secreting herpes viral mutants effectively treat tumor in a murine metastatic colorectal liver model by oncolytic and T-cell-dependent mechanisms. Cancer Gene Ther, 2007, 14: 590-597.
73. Wong R J, Chan M K, Yu Z, et al. Effective intravenous therapy of murine pulmonary metastases with an oncolytic herpes virus expressing interleukin 12. Clin Cancer Res, 2004, 10: 251-259.
74. Wong R J, Patel S G, Kim S, et al. Cytokine gene transfer enhances herpes oncolytic therapy in murine squamous cell carcinoma. Hum Gene Ther, 2001, 12: 253-265.
75. Campadelli-Fiume G, De Giovanni C, Gatta V, et al. Rethinking herpes simplex virus: the way to oncolytic agents. Rev Med Virol, 2011, 21: 213-226.
76. Serafini P, Carbley R, Noonan K A, et al. High-dose granulocyte-macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells. Cancer Res, 2004, 64: 6337-6343.
77. Kaur B, Cripe T P, Chiocca E A. "Buy one get one free": armed viruses for the treatment of cancer cells and their microenvironment. Curr Gene Ther, 2009, 9: 341-355.